Both Netflix and Google displayed similar bullish patterns. Netflix' daily chart displayed a bullish pennant pattern, while Google's just made a new all-time high.
Cramer said he was in agreement with Lang's analysis, saying investors need to forget about Dell and go where the action is, and that's with "FANG."
In the "Executive Decision" segment, Cramer spoke with Sandy Cutler, chairman and CEO of
(ETN), which just beat earnings expectations by 4 cents a share. Cramer currently owns shares of Eaton for his charitable trust,
Cutler updated investors on Eaton's acquisition with Cooper Industries, which closed in November. He said the combined company is now a "more capable supplier" to its customers and offers a powerful package of power management solutions. Eaton is now well-positioned, said Cutler, and the synergies are only starting be realized.Cutler also offered an update on Eaton's business in China. He said the construction equipment business in China has been stalled since the spring of 2011, but January saw the first positive sign of strength for the region. He said while one month does not make a trend, you can't have a trend without that first month. When asked about America's aging electrical grid in the wake of Hurricane Sandy and the power outage at this year's Super Bowl on Sunday, Cutler said much work needs to be done in that area. The Cooper acquisition now gives Eaton more exposure to the utility industry. Cutler noted that Eaton will primarily be an electrical, hydraulic and aerospace company. Cramer said Eaton remains a stock that should be in every investor's portfolio.
Lightning RoundIn the Lightning Round, Cramer was bullish on McKesson (MCK), Phillips 66 (PSX), Life Technologies (LIFE) and KeyCorp (KEY). Cramer was bearish on DuPont (DD), Arena Pharmaceuticals (ARNA) and New York Community Bancorp (NYCB).
Bullish on BotoxIn the second "Executive Decision" segment, Cramer once spoke with David Pyott, resident and CEO of Allergan (AGN), a stock that's up 20% since Cramer last spoke with Pyott in September. Pyott said Allergan continues to have a lot on tap and the company's future continues to look very bright. He said his company's acquisition of MAP Pharmaceuticals will be a big boost to Allergan's inhaled migraine treatments, which can potentially be given to 10 times as many patients as its current injected Botox treatments. Pyott noted that any time you can give patients an in-home treatment rather than a hospital stay, costs are lessened and patient convenience is increased. Pyott was also bullish on Botox's prospects in the treatment of overactive bladder. He said the data continue to be very positive. Also positive, Eyelea, Allergan's treatment for macular degeneration. He said the latest data are signaling Eyelea may be effective for up to three or four months, which would lessen the number of injections a patient must receive from 10 a year to just three or four. Cramer remained bullish on Allergan.
No Huddle OffenseIn his "No Huddle Offense" segment, Cramer summed up his many conversations with company executives at this weekend's Super Bowl festivities in New Orleans. He said not a single exec complained about President Obama or having to pay higher taxes. Instead, they simply expressed relief that Washington is now off the front page of the newpapers. Cramer said that, overall, corporate execs seemed to be optimistic that economic expansion is underway and the American consumer is alive and well. They were bullish on housing, he noted, and on American oil and gas. The markets needed certainty, he concluded, and now they seem to have gotten it. To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here. To watch replays of Cramer's video segments, visit the Mad Money page on CNBC. -- Written by Scott Rutt in Washington, D.C. To email Scott about this article, click here: Scott Rutt Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts